The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients

Wagg, Adrian; Cardozo, Linda; Nitti, Victor W.; Castro-Diaz, David; Auerbach, Stephen; Blauwet, Mary Beth; Siddiqui, Emad
September 2014
Age & Ageing;Sep2014, Vol. 43 Issue 5, p666
Academic Journal
Introduction: mirabegron is a β3-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB). As the prevalence of OAB increases with age, a prospective subanalysis of individual and pooled efficacy and tolerability data from three 12-week, randomised, Phase III trials, and of tolerability data from a 1-year safety trial were conducted in order to evaluate the efficacy and tolerability of mirabegron in subgroups of patients aged ≥65 and ≥75 years.Methods: primary efficacy outcomes were change from baseline to final visit in the mean number of incontinence episodes/24 h and the mean number of micturitions/24 h. Tolerability was assessed by the incidence of treatment-emergent adverse events (TEAEs).Results: over 12 weeks mirabegron 25 mg and 50 mg once-daily reduced the mean numbers of incontinence episodes and micturitions/24 h from baseline to final visit in patients aged ≥65 and ≥75 years. Mirabegron was well tolerated: in both age groups, hypertension and urinary tract infection were among the most common TEAEs over 12 weeks and 1 year. The incidence of dry mouth, a typical anticholinergic TEAE, was up to sixfold higher among the older patients randomised to tolterodine than any dose of mirabegron.Conclusions: these analyses have demonstrated the efficacy of mirabegron over 12 weeks and the tolerability of mirabegron over 12 weeks and 1 year in OAB patients aged ≥65 and ≥75 years, supporting mirabegron as a therapeutic option in older patients with OAB.


Related Articles

  • Mirabegron available to treat overactive bladder.  // British Journal of Hospital Medicine (17508460);Mar2013, Vol. 74 Issue 3, p129 

    The article reports that use of a first-in-class once-daily oral beta 3 adrenoceptor agonist Mirabegron in different treatments.

  • Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. Loymans, Rik J. B.; Gemperli, Armin; Cohen, Judith; Rubinstein, Sidney M.; Sterk, Peter J.; Reddel, Helen K.; Jüni, Peter; ter Riet, Gerben // BMJ: British Medical Journal;5/17/2014, Vol. 348 Issue 7958, p12 

    The article discusses a study on reducing the exacerbation of asthma with combined inhaled corticosteroids and long acting beta agonists. Topics addressed include the use of the combined drugs as maintenance and reliever treatment or as a fixed daily dose, withdrawals resulting from adverse...

  • Mirabegron -- promising new drug for overactive bladder syndrome. Rigby, Debbie // Australian & New Zealand Continence Journal;Winter2015, Vol. 21 Issue 2, p40 

    The article discusses the potential therapeutic use of antimuscarinic agent Mirabegron in treating patients with urinary incontinence (UI) and overactive bladder (OAB) syndrome. Information regarding the drugs adverse health effects, prescribed dosage, and tolerance, are discussed. The article...

  • Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome. Sanford, Mark // Drugs;2013, Vol. 73 Issue 11, p1213 

    Mirabegron (YM178, Myrbetriq™, Betanis, Betmiga™) is a β-adrenergic receptor agonist approved in several countries for the symptomatic treatment of adults with overactive bladder syndrome. In three 12-week, randomized, double-blind, placebo-controlled, multinational trials in...

  • Presente y futuro del tratamiento farmacol�gico de la vejiga hiperactiva. Mu�oz G�lligo, E.; Garc�a Garc�a-Porrero, A.; Masero Casasola, A. R.; Mu�oz Garrido, F. // Suelo P�lvico;2012, Vol. 8 Issue 3, p64 

    The overactive bladder syndrome has a complex physiopathological basis, which implies muscular and neural systems and a complex array of molecular intermediaries. In fact, in our days the pharmacological treatment, based on anticholinergics drugs, is not effective in a great proportion of...

  • Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma. Beeh, Kai-Michael; LaForce, Craig; Gahlemann, Martina; Wenz, Arne; Toorawa, Robert; Fležar, Matjaž // Respiratory Research;Jul2015, Vol. 16 Issue 1, p1 

    Background: A Phase II, multicentre, randomised, double-blind, placebo-controlled, crossover trial comparing the 24-h forced expiratory volume in 1 s (FEV1) time profile after 3 weeks' treatment with once-daily (QD) or twice-daily (BID) olodaterol (at the same total daily dose) versus placebo...

  • Overactive Bladder and the β-Adrenoceptor Agonists: Current Strategy and Future Prospects. Giarenis, Ilias; Robinson, Dudley; Cardozo, Linda // Drugs;Oct2015, Vol. 75 Issue 15, p1707 

    Overactive bladder (OAB) is a clinical syndrome describing the symptom complex of urgency, with or without urgency incontinence, and is usually associated with frequency and nocturia. It is a common, under-diagnosed and therefore under-treated condition that can have a detrimental effect on...

  • Mirabegron: a guide to its use in overactive bladder syndrome in the EU. Sanford, Mark; Lyseng-Williamson, Katherine // Drugs & Therapy Perspectives;Apr2015, Vol. 31 Issue 4, p107 

    Mirabegron (Betmiga™), a β-adrenergic receptor agonist, is a useful option for the treatment of overactive bladder syndrome. In clinical trials in this patient population, oral mirabegron 50 mg once daily significantly reduced incontinence and micturition episodes, consistently reduced...

  • Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD. Murphy, Lorraine; Rennard, Stephen; Donohue, James; Molimard, Mathieu; Dahl, Ronald; Beeh, Kai-Michael; Dederichs, Juergen; Fülle, Hans-Jürgen; Higgins, Mark; Young, David // Drugs;Sep2014, Vol. 74 Issue 14, p1635 

    Indacaterol is the first once-daily, long-acting β-adrenergic agonist (LABA) approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol was developed using a combination of informed drug design and molecular chemistry to generate a β-adrenergic agonist with a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics